Technologies

CAMH scientists have identified an interaction between dopamine transporter DAT and the presynaptic dopamine type 2 receptor (D2) which is thought to be an underlying cause for Attention Deficit Hyperactivity Disorder (ADHD). By characterizing this interaction, our scientists have developed a peptide that interferes with this coupling. As a result, this interfering peptide could lead to the development of a breakthrough therapy capable of delivering enhanced affinity, better efficacy, and a superior side-effect profile.